ArticleDiscover oncology2026
Pan-cancer multi-omics profiling of gasdermins identifies GSDMD as an immune-related prognostic biomarker in kidney renal clear cell carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe genomic and epigenetic landscape of the gasdermin family across cancers, and its clinical relevance, remain incompletely defined.
methodsMulti-omics features of gasdermins across 33 cancer types were analyzed using TCGA data, including RNA-seq, SNV, CNV, DNA methylation, and clinical outcomes. RPPA data were obtained from TCPA, and pharmacogenomic drug response data from GDSC and CTRP. A nomogram for overall survival was developed and externally evaluated in independent KIRC cohorts from GEO (GSE29609), ICGC (RECA-EU), and CPTAC (CPTAC-3-CCRCC). The relationship between GSDMD and immune checkpoint markers was further examined in an exploratory IHC cohort.
resultsGasdermin family members showed differential expression across cancers, with expression changes partially concordant with CNV and DNA methylation patterns and associated with prognosis in multiple tumor types. In KIRC, GSDMD stood out with consistently increased mRNA expression accompanied by frequent CNV events and hypomethylation, and these features were associated with unfavorable overall survival and progression-free survival. Higher GSDMD expression was also associated with pathway activity scores and immune-related features in KIRC, including immune infiltration estimates and co-expression patterns of immune checkpoint molecules. Analyses based on public pharmacogenomic resources suggested associations between GSDMD and predicted sensitivity profiles for selected chemotherapeutic and targeted agents. A nomogram integrating GSDMD and immune score showed good prognostic performance, with time-dependent AUCs > 0.75 in external cohorts. In the exploratory IHC cohort (n = 22), GSDMD showed a positive association with CTLA4, a similar trend with LAG3, and an inverse trend with PD-1/PD-L1.
conclusionsThis integrative analysis supports GSDMD as an immune-related prognostic biomarker candidate in KIRC and provides a framework for further mechanistic and clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.